Woodford fund's £550mln biotech rescue stalls

The fund was given a period of exclusivity to find investors willing to purchase illiquid holdings but it missed the deadline

BlackRock - Neil Woodford’s Equity Income fund fails £550mln biotech startups rescue deal

A £550mln deal to rescue a portfolio of investments made by Neil Woodford in biotech startups has collapsed, raising concerns it might lead to a fire sale of 20 companies.

Boutique investment bank WG Partners tried to assemble a group of investors to save the fund’s illiquid holdings but missed the deadline.

READ: Law firms probe Hargreaves Lansdown as part of Woodford challenge

Administrator Link Fund Solutions is overseeing the liquidation of the holdings of Woodford's former flagship fund, which was suspended last June after a wave of redemption requests.

In late January, Equity Income investors received their first payout, worth between 48p and 58p for a pound, following the sale of the listed portion of the portfolio by BlackRock.

Park Hill, a division of PJT Partners Inc (NYSE:PJT), is working with Link to try and sell the remaining 26% of the portfolio, made up of the illiquid holdings, which are harder to sell.

These include stakes in small biotech firms, such as gene analysis company Oxford Nanopore, a company said to be worth over US$1bn.

In November, PJT Partners granted WG Partners a period of exclusivity to find a group of investors willing to purchase the biotech portfolio but the deal has now fallen through.

“It is in the best interests of all investors for the fund to be wound up on the basis of an ‘orderly realisation’ of the fund’s assets, which involves the sale of the fund’s assets over a reasonable period of time,” Link told City AM.

Quick facts: BlackRock

Price: 545.51 USD

Market: NYSE
Market Cap: $83.24 billion

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...


Q BioMed CEO says Strontium89 has received a warm response and enthusiasm...

Q BioMed Inc (OTCQB:QBIO) CEO Denis Corin tells Proactive the biotech has seen commercial uptake of Strontium89, its FDA-approved drug for the non-opioid treatment of metastatic cancer in the bone. Corin says while the coronavirus pandemic slowed the diagnosis and treatment of cancer in many...

2 hours, 53 minutes ago

2 min read